Document is current
Any future updates will be listed below
-
Authors
Fogh-Andersen, Ida Stisen https://orcid.org/0000-0002-5328-9907
Sørensen, Jens Christian Hedemann https://orcid.org/0000-0001-5139-7405
Petersen, Anja Sofie https://orcid.org/0000-0002-0125-6038
Jensen, Rigmor Højland https://orcid.org/0000-0001-6433-5887
Meier, Kaare https://orcid.org/0000-0001-7677-406X
- License Information
-
More Information
Article History
Received: 29 November 2025
Accepted: 19 February 2026
First Online: 9 March 2026
Declarations
:
: The protocol was approved by the independent regional scientific ethics committee (permit number VEK: 1-10-72-36-21). The Central Denmark Region authorized the acquisition, storage, and analysis of data (permit number 1-16-02-577-20). All participants provided signed informed consent before enrolling in the study.
: Not applicable.
: JCHS has received a restricted research grant (for the institution) from the Novo Nordisk Foundation. KM has received teaching fees from Medtronic and consulting fees from Salvia BioElectronics. KM and JCHS are co-owners and co-founders of the neuromodulation database company Neurizon. RJ received restricted research grants (for the institution) from Lundbeck Pharma and the Novo Nordisk Foundation. RJ has received personal fees for educational and teaching activities from Pfizer, Teva, Novartis, Abbvie, Lundbeck Pharma, and Eli-Lilly, and a fee (for the institution) for serving on the Lundbeck Pharma Advisory Board. RJ is the chair of the Master of Headache Disorders, Director of the Danish Headache Center, and unpaid activities as Director in Lifting the Burden. ASP has received a restricted research grant (for the institution), conference attendance from Lundbeck Pharma, and personal fees from Pfizer for teaching activities. ISFA has nothing to declare.
